Observations: For 2019, Express Scripts reported that specialty trend was -5.2% for plans in its SaveonSP specialty patient assistance solution vs
In 2019, PT141 (bremelanotide) was approved by the United States Food and Drug Administration (FDA) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
The timing of symptom onset, presence of other features (such as fever, cough, or nasal congestion), and response to standard treatments can help differentiate between these possibilities
Both drugs have similar side effect profiles, with gastrointestinal issues being the most common
Starting Dose The recommended starting dosage of Semaglutide or Compounded Semaglutide is 0.25 mg weekly for the first month (5 units on the syringe). This amount is just meant to introduce the medication into your system so it can begin acclimation
Participants will receive two courses of the treatment spaced six months apart